🔗 Share this article World Health Organization Issues Warning Over Critical Shortage of Weight-Loss Medications Under a tenth of individuals who could benefit from obesity jabs like Wegovy can access them, caution the WHO as it publishes its first advice on the medications. With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for increased and just access to GLP-1 medication. Based on forecasts, over two billion will be living with obesity by 2030 without intervention. "The latest guidance affirms that excess weight is a chronic disease that can be addressed with holistic and lifelong support," stated its chief Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are major obstacles to widespread availability to the treatments that can aid individuals in losing significant weight, explains the organization. Skinny Jab Scarcity Even under the present most favorable case, the manufacturing of these medications would only suffice for around 100 million people – fewer than 10% of eligible patients, according to the WHO. The advice calls on nations and manufacturers to increase availability, through measures like patent sharing. A patent on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in several countries in 2026. How Weight-Loss Jabs Function GLP-1 drugs imitate a body's own hormone to reduce digestion speed, reduce hunger and increase the sense of being full so people consume fewer calories. Individuals commonly begin shedding pounds after several weeks of beginning the once-weekly jabs. Research points to users may put most of the weight back on within a year of discontinuing the medication, as their normal food cravings come back. To be carrying excess weight elevates your likelihood for developing medical conditions, such as type 2 diabetes, heart disease, brain attack, and specific malignancies. Obesity impacts people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
Under a tenth of individuals who could benefit from obesity jabs like Wegovy can access them, caution the WHO as it publishes its first advice on the medications. With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for increased and just access to GLP-1 medication. Based on forecasts, over two billion will be living with obesity by 2030 without intervention. "The latest guidance affirms that excess weight is a chronic disease that can be addressed with holistic and lifelong support," stated its chief Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are major obstacles to widespread availability to the treatments that can aid individuals in losing significant weight, explains the organization. Skinny Jab Scarcity Even under the present most favorable case, the manufacturing of these medications would only suffice for around 100 million people – fewer than 10% of eligible patients, according to the WHO. The advice calls on nations and manufacturers to increase availability, through measures like patent sharing. A patent on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in several countries in 2026. How Weight-Loss Jabs Function GLP-1 drugs imitate a body's own hormone to reduce digestion speed, reduce hunger and increase the sense of being full so people consume fewer calories. Individuals commonly begin shedding pounds after several weeks of beginning the once-weekly jabs. Research points to users may put most of the weight back on within a year of discontinuing the medication, as their normal food cravings come back. To be carrying excess weight elevates your likelihood for developing medical conditions, such as type 2 diabetes, heart disease, brain attack, and specific malignancies. Obesity impacts people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.